Discussion
tumor, breast cancer
ADVERSE EVENTS, TUMOR, METASTASIS, BREAST CANCER
Endocrine therapy is a standard of care for ER+/HER2- MBC, and chemotherapy is the second approach. Unfortunately, resistance eventually develops in MBC and becomes a major clinical challenge. There is a need to find new therapeutic strategies to improve treatment outcomes. Angiogenesis promotes tumor invasion and metastasis,The adverse events observed in this study were mainly due to apatinib. The safety profile of apatinib in our study was consistent with that reported in the other breast cancer study,